---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-008332"
form_type: "8-K"
ticker: null
cik: "0001113148"
company_name: "INFINITY PHARMACEUTICALS, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:28:35.761837+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Infinity Pharma to merge with MEI Pharma; Infinity stockholders to receive 1.0449 MEI shares per share

## Summary
- Merger consideration: each Infinity share converts into 1.0449 MEI shares; Infinity stockholders will own ~42% of combined company on fully diluted basis.
- Closing conditions include stockholder approvals, regulatory, and net cash conditions: MEI must have ≥$80M net cash if close by June 30, 2023; Infinity must have ≥$4M net cash.
- Termination fees: MEI pays Infinity $4M under certain circumstances; Infinity pays MEI $2.9M under certain circumstances.
- Post-merger leadership: David M. Urso as CEO, Robert Ilaria Jr. as CMO, Stéphane Peluso as CSO; board 8 members (4 MEI, 3 Infinity, 1 joint).
- Infinity reduces headcount by 4 positions (~13%) with ~$2M costs in Q1 2023; Lawrence Bloch terminated, Adelene Perkins appointed PFO.

## SEC filing metadata
- accession: 0001140361-23-008332
- form_type: 8-K
- cik: 0001113148
- company_name: INFINITY PHARMACEUTICALS, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.05, 5.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/0001140361-23-008332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/brhc10048558_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-008332
- JSON: https://secwatch.observer/filing/0001140361-23-008332.json
- Plain text: https://secwatch.observer/filing/0001140361-23-008332.txt

## Key facts
- Executive change
  Adelene Perkins was terminated as other_named_officer at INFINITY PHARMACEUTICALS, INC..
  - Action: terminated
  source text: Upon, and in connection with, the closing of the Merger, Ms. Perkins’s employment with Infinity will terminate without Cause and she will join the MEI Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/0001140361-23-008332-index.htm
- Governance Changes
  INFINITY PHARMACEUTICALS, INC.: Adopted an amendment to the Amended and Restated Bylaws to add a new Section 6 of Article IX designating the Court of Chancery of Delaware as the exclusive forum for certain legal actions (effective 2023-02-22).
  - Change: bylaw amendment
  - Effective: 2023-02-22
  source text: On February 22, 2023, Infinity’s Board of Directors adopted an amendment to Infinity’s Amended and Restated Bylaws (the “Bylaw Amendment”) to add a new Section 6 of Article IX thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/0001140361-23-008332-index.htm
- Material Agreements
  INFINITY PHARMACEUTICALS, INC. entered into Agreement and Plan of Merger with MEI Pharma, Inc. and Meadow Merger Sub, Inc. (effective 2023-02-22).
  - Action: entry
  - Agreement: merger
  - Counterparty: MEI Pharma, Inc. and Meadow Merger Sub, Inc.
  - Effective: 2023-02-22
  source text: On February 22, 2023, Infinity Pharmaceuticals, Inc., a Delaware corporation (“Infinity” or the “Company”), MEI Pharma, Inc., a Delaware corporation (“MEI”), and Meadow Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of MEI (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/0001140361-23-008332-index.htm
- Restructurings & Charges
  INFINITY PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $2 million (4 positions, representing approximately 13% of the Company’s workforce).
  - Type: restructuring
  - Charge: approximately $2 million
  - Headcount: 4 positions, representing approximately 13% of the Company’s workforce
  source text: On February 22, 2023, the Board of Directors of the Company approved a strategic restructuring of the Company to preserve the Company’s resources upon the signing of the Merger Agreement. The Company will reduce its overall headcount by 4 positions, representing approximately 13% of the Company’s workforce, in the first quarter of 2023. The Company currently expects to incur approximately $2 million in the first quarter of 2023 in connection with this workforce reduction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123008332/0001140361-23-008332-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.